Literature DB >> 26219723

Renal involvement in tuberous sclerosis complex with emphasis on cystic lesions.

Arthur Robert1, Valerie Leroy2, Audrey Riquet3, Lucile Gogneaux4, Nathalie Boutry5, Fred E Avni5.   

Abstract

INTRODUCTION: Tuberous sclerosis complex (TSC) involves frequently the kidneys. Lesions encompass mainly angiomyolipoma and cysts. The disease can be associated with autosomal dominant polycystic kidney disease leading to the contiguous gene syndrome (CGS) The objectives of the present study were to review the US appearances of the renal involvement in children affected by classical TSC or by the CGS and to verify whether it is possible to differentiate between both entities. The evolution of the lesions through time was also studied.
MATERIALS AND METHODS: 55 cases of patients <16 years with STB were reviewed by two pediatric radiologists. Clinical data reviewed included age at diagnosis, genetic assessment and complications; US data reviewed included renal size, type of lesions (angiomyolipoma-AML, or cysts), number and location as well as their evolution with time. Complications were also analyzed.
RESULTS: 30 patients (56 %) had at least one kidney lesion (27 classical TSC and 3 CGS). On the basis of the US findings, these patients were separated into four groups. Group 1 (9 patients) displayed microscopic (diffuse) AML; group 2 (3 patients) displayed macroscopic AML; group 3 (9 patients) displayed only renal cysts and group 4 (9 patients) displayed the association of AML and cysts. Increased renal size, the large number and size of cystic lesions were suggestive of the CGS. The isolated AML were suggestive of classical STB. The average growth of angiomyolipoma was low before age of 12 and exceeded 4 mm/year thereafter.
CONCLUSION: In children with TSC, renal involvement is common. Some US criteria can help to suggest the diagnosis of CGS. The growth of angiomyolipoma is slow before 12 years and accelerates thereafter. Complications are rare.

Entities:  

Keywords:  Angiomyolipoma; Children; Contiguous gene syndrome; Cysts; Renal involvement; Tuberous sclerosis complex

Mesh:

Year:  2015        PMID: 26219723     DOI: 10.1007/s11547-015-0572-7

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  21 in total

Review 1.  Tuberous sclerosis complex renal disease.

Authors:  Bradley P Dixon; John C Hulbert; John J Bissler
Journal:  Nephron Exp Nephrol       Date:  2010-11-11

Review 2.  Long-Term Everolimus Treatment in Individuals With Tuberous Sclerosis Complex: A Review of the Current Literature.

Authors:  Lily H Tran; Mary L Zupanc
Journal:  Pediatr Neurol       Date:  2014-11-08       Impact factor: 3.372

3.  Imaging features of tuberous sclerosis complex with autosomal-dominant polycystic kidney disease: a contiguous gene syndrome.

Authors:  Susan J Back; Savvas Andronikou; Tracy Kilborn; Bernard S Kaplan; Kassa Darge
Journal:  Pediatr Radiol       Date:  2014-10-30

4.  Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors.

Authors:  S K Rakowski; E B Winterkorn; E Paul; D J R Steele; E F Halpern; E A Thiele
Journal:  Kidney Int       Date:  2006-09-27       Impact factor: 10.612

5.  Renal lesion growth in children with tuberous sclerosis complex.

Authors:  D H Ewalt; E Sheffield; S P Sparagana; M R Delgado; E S Roach
Journal:  J Urol       Date:  1998-07       Impact factor: 7.450

6.  A cross sectional study of renal involvement in tuberous sclerosis.

Authors:  J A Cook; K Oliver; R F Mueller; J Sampson
Journal:  J Med Genet       Date:  1996-06       Impact factor: 6.318

7.  Causes of death in patients with tuberous sclerosis.

Authors:  C W Shepherd; M R Gomez; J T Lie; C S Crowson
Journal:  Mayo Clin Proc       Date:  1991-08       Impact factor: 7.616

8.  Identification and characterization of the tuberous sclerosis gene on chromosome 16.

Authors: 
Journal:  Cell       Date:  1993-12-31       Impact factor: 41.582

9.  Facilitated diagnosis of the contiguous gene syndrome: tuberous sclerosis and polycystic kidneys by means of haplotype studies.

Authors:  R Torra; C Badenas; A Darnell; J A Camacho; R Aspinwall; P C Harris; X Estivill
Journal:  Am J Kidney Dis       Date:  1998-06       Impact factor: 8.860

Review 10.  Is mTOR inhibition a systemic treatment for tuberous sclerosis?

Authors:  Romina Moavero; Antonella Coniglio; Francesco Garaci; Paolo Curatolo
Journal:  Ital J Pediatr       Date:  2013-09-17       Impact factor: 2.638

View more
  1 in total

1.  Beyond polycystic kidney disease.

Authors:  Susana Franco Santos; Telma Francisco; Ana Isabel Cordeiro; Maria João Paiva Lopes
Journal:  BMJ Case Rep       Date:  2017-10-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.